Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ardelyx Inc ARDX

Healthcare Biotechnology
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control... see more

Recent & Breaking News (NDAQ:ARDX)

Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire April 16, 2021

Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan

PR Newswire April 14, 2021

Ardelyx Announces Upcoming Data Presentation at ISN World Congress of Nephrology 2021

PR Newswire April 12, 2021

Ardelyx Announces Poster Presentations, Educational Symposium, and Exhibitor Showcase at National Kidney Foundation 2021 Virtual Spring Clinical Meetings

PR Newswire March 30, 2021

Ardelyx Appoints Muna Bhanji, R.Ph, to its Board of Directors

PR Newswire March 15, 2021

Ardelyx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights

PR Newswire March 8, 2021

Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA(TM) - New Innovative Treatment for Irritable Bowel Syndrome with Constipation

GlobeNewswire March 1, 2021

Ardelyx to Present at the 10th Annual SVB Leerink Global Healthcare Conference

PR Newswire February 17, 2021

Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

PR Newswire November 23, 2020

Ardelyx to Present at the Jefferies Virtual London Healthcare Conference

PR Newswire November 10, 2020

Ardelyx to Webcast Virtual Analyst Day

PR Newswire November 6, 2020

Ardelyx Reports Third Quarter 2020 Financial Results and Business Highlights

PR Newswire November 5, 2020

Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020

PR Newswire October 22, 2020

Ardelyx Launches 'Can We Do Better?' Campaign at ASN's Kidney Week 2020

PR Newswire October 22, 2020

Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020

PR Newswire October 12, 2020

Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

PR Newswire September 15, 2020

Ardelyx to Participate in Three Upcoming Investor Conferences in September

PR Newswire September 8, 2020

Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights

PR Newswire August 6, 2020

Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor

PR Newswire August 3, 2020

Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

PR Newswire June 30, 2020